BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Doxorubicin: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: InSightec, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Spirovant Sciences, Inc., Merck Sharp & Dohme LLC, Zhejiang Teruisi Pharmaceutical Inc., Incyte Corporation, Celgene, Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers | not yet recruiting | 430 |
| 2026-12-31 est. | P1/P2 | Spirovant Sciences, Inc. | NCT06526923 A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) | Cystic Fibrosis | recruiting | 15 |
| 2027-02-12 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | active not recruiting | 340 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-01 est. | P1/P2 | Zhejiang Teruisi Pharmaceutical Inc. | NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | not yet recruiting | 66 |
| 2026-09-01 est. | P3 | Incyte Corporation INCY | NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | active not recruiting | 899 |
| 2026-06-19 | P2 | Celgene | NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | Lymphoma, Follicular | active not recruiting | 95 |
| 2026-06 est. | P1/P2 | InSightec | NCT05630209 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Brain Tumor | active not recruiting | 10 |
| 2026-06 est. | P1/P2 | InSightec | NCT05615623 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | Brain Tumor | active not recruiting | 10 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-31 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | recruiting | 440 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.